ETON Eton Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1710340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY100.6%
TTM net income YoY846.2%
TTM EPS YoY703.3%
Revenue 3-yr CAGR62.6%
Net income 3-yr CAGR181.6%
Margins
Gross margin69.2%
Operating margin28.8%
Net margin35.3%
FCF margin27.1%
EBITDA margin31.4%
Returns
ROE90.6%
ROA38.1%
ROIC (approx.)115.0%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets44.7%
Debt / equity0.27x
Current ratio1.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio8.8%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $79.95M | $39.01M |
| Cost of revenue | $37.21M | $15.60M |
| Gross profit | $42.74M | $23.41M |
| R&D expense | $7.76M | $3.25M |
| SG&A expense | $35.82M | $22.75M |
| Operating income | -$844,000 | -$2.60M |
| Interest expense | $4.78M | $2.00M |
| Pretax income | -$4.56M | -$3.81M |
| Income tax | $43,000 | $15,000 |
| Net income | -$4.60M | -$3.82M |
| EBITDA | $3.20M | -$1.45M |
| EPS (basic) | -0.17 | -0.15 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $25.94M | $14.94M |
| Receivables | $11.76M | $5.36M |
| Inventory | $15.42M | $15.23M |
| Current assets | $60.58M | $41.02M |
| PP&E, net | $326,000 | $34,000 |
| Intangibles | $30.88M | $34.88M |
| Total assets | $92.11M | $76.12M |
| Current liabilities | $38.49M | $19.95M |
| Short-term debt | $8.79M | $0 |
| Long-term debt | $21.77M | $29.81M |
| Total debt | $30.56M | $29.81M |
| Total liabilities | $65.96M | $51.70M |
| Shareholders' equity | $26.15M | $24.43M |
| Net debt | $4.62M | $14.88M |
| Shares outstanding | 27.05M | 26.71M |
| Cash flow statement | ||
| Operating cash flow | $10.52M | $969,000 |
| Capital expenditure | $333,000 | $26,000 |
| Free cash flow | $10.19M | $943,000 |
| Investing cash flow | -$333,000 | -$40.01M |
| Financing cash flow | $815,000 | $32.59M |
| Depreciation & amortization | $4.04M | $1.15M |
| Stock-based compensation | $5.51M | $3.17M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.